Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2021 Filed Jan 27, 2021 22:03 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
SaleCommon Stock | 4,116 | $99.00 | $407,484.00 |
DisclosureSEC source: 0001209191-21-005711 · doc4.xml · nonDerivative · entry 2 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,158 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:03 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
Exercise / conversionCommon Stock | 4,116 | $72.86 | $299,891.76 |
DisclosureSEC source: 0001209191-21-005711 · doc4.xml · nonDerivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:52 UTC |
Flannelly Barry PEVP & General Manager US
|
SaleCommon Stock | 2,744 | $100.00 | $274,400.00 |
DisclosureSEC source: 0001209191-21-005694 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,994 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 44,704 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:46 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 78 | $100.50 | $7,839.00 |
DisclosureSEC source: 0001209191-21-005686 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,452 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 26,577 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:43 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 78 | $100.50 | $7,839.00 |
DisclosureSEC source: 0001209191-21-005682 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,135 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,055 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 22:02 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 174 | $93.96 | $16,349.04 |
DisclosureSEC source: 0001209191-21-004354 · doc4.xml · nonDerivative · entry 3 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,530 F3 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F4 · balance_after: Including the January 15, 2021 Restricted Stock Unit Grants, this includes an aggregate of 27,686 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:44 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 174 | $93.96 | $16,349.04 |
DisclosureSEC source: 0001209191-21-004334 · doc4.xml · nonDerivative · entry 2 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,213 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: Including the January 15, 2021 Restricted Stock Unit Grant, this includes an aggregate of 16,164 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:02 UTC |
Stamoulis ChristianaEVP & Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004447 · doc4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F3 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:02 UTC |
Stamoulis ChristianaEVP & Chief Financial Officer
|
GrantCommon Stock | 11,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004447 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,821 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Christiana Stamoulis's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 15, 2021 Restricted Stock Unit Grant, this includes an aggregate of 31,397 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:40 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004418 · doc4.xml · derivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F4 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:40 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
GrantCommon Stock | 11,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004418 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,784 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Wenqing Yao's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 15, 2020 Restricted Stock Unit Grant, this includes an aggregate of 108,222 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. F3 · balance_after: This total excludes 24,589 shares that were erroneously reported as being owned by the reporting person in the reporting persons Form 4 filed on June 22, 2020 and three Forms 4 filed by the reporting person after that date. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:14 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004378 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F3 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:14 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantCommon Stock | 23,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004378 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,744 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Steven Stein's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 15, 2021 Restricted Stock Unit Grant, this includes an aggregate of 119,744 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:07 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004365 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F3 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:07 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantCommon Stock | 11,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004365 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,738 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Barry Flannelly's continued service with the issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 17, 2020 Restricted Stock Unit Grant, this includes an aggregate of 44,704 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:02 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
GrantCommon Stock | 5,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004354 · doc4.xml · nonDerivative · entry 2 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,704 F2 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Morrissey's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:02 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
GrantCommon Stock | 11,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004354 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,943 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Michael Morrissey's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:51 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,534 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004342 · doc4.xml · derivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,534 Underlying: Common Stock · 2,534 shares Expires 2031-01-14 F3 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:51 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantCommon Stock | 4,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004342 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,427 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Paul Trower's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 15, 2021 Restricted Stock Unit Grant, this includes an aggregate of 16,058 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:44 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
GrantCommon Stock | 5,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004334 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,387 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Dickinson's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:38 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantEmployee Stock Option (right to buy) · Derivative | 74,720 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004324 · doc4.xml · derivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,720 Underlying: Common Stock · 74,720 shares Expires 2031-01-14 F1 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:35 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004315 · doc4.xml · derivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F1 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:31 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004306 · doc4.xml · derivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F1 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:28 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004300 · doc4.xml · derivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F1 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:25 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004295 · doc4.xml · derivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F1 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:15 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 127 | $0.00 Strike: $65.36 | $0.00 |
DisclosureSEC source: 0001209191-21-003414 · doc4.xml · derivative · entry 2 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,931 Underlying: Common Stock · 127 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning April 9, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:15 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionCommon Stock | 127 | $65.36 | $8,300.72 |
DisclosureSEC source: 0001209191-21-003414 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This includes an aggregate of 23,784 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:34 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 136 | $86.45 | $11,757.20 |
DisclosureSEC source: 0001209191-21-002103 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,421 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of resticted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 12,869 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:26 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 136 | $86.45 | $11,757.20 |
DisclosureSEC source: 0001209191-21-002075 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,626 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of resticted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 12,869 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 23:31 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 343 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-21-000030 · doc4_6975.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 29,314,152 F4 · price: 343 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F4 · ownership.nature: 343 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, the non-qualified stock options ("Stock Options"), Common Stock issued upon exercise of Stock Options, restricted stock units (each an "RSU") payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest). F7 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F8 · ownership.nature: Includes beneficial ownership of 5,369 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 2,802 shares of Common Stock received from RSUs and 155,000 shares of Common Stock received from exercise of 155,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion. F9 · ownership.nature: The 343 shares are reported for each of the Funds as each has an indirect pecuniary interest. F10 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F12 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 23:31 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 343 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-21-000030 · doc4_6975.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,850,385 F4 · price: 343 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F4 · ownership.nature: 343 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, the non-qualified stock options ("Stock Options"), Common Stock issued upon exercise of Stock Options, restricted stock units (each an "RSU") payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest). F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F8 · ownership.nature: Includes beneficial ownership of 5,369 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 2,802 shares of Common Stock received from RSUs and 155,000 shares of Common Stock received from exercise of 155,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion. F9 · ownership.nature: The 343 shares are reported for each of the Funds as each has an indirect pecuniary interest. F10 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F12 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:00 UTC |
HARRIGAN EDMUNDDirector
|
GrantCommon Stock | 207 | $86.98 | $18,004.86 |
DisclosureSEC source: 0001209191-21-001236 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,492 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:55 UTC |
Clancy Paul JDirector
|
GrantCommon Stock | 281 | $86.98 | $24,441.38 |
DisclosureSEC source: 0001209191-21-001226 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,796 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:51 UTC |
FOUSE JACQUALYN ADirector
|
GrantCommon Stock | 237 | $86.98 | $20,614.26 |
DisclosureSEC source: 0001209191-21-001217 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,259 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:48 UTC |
BIENAIME JEAN JACQUESDirector
|
GrantCommon Stock | 275 | $86.98 | $23,919.50 |
DisclosureSEC source: 0001209191-21-001207 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,921 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:45 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 213 | $86.98 | $18,526.74 |
DisclosureSEC source: 0001209191-21-001195 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,653 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:51 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 128 | $0.00 Strike: $65.36 | $0.00 |
DisclosureSEC source: 0001209191-20-063508 · doc4.xml · derivative · entry 2 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 Underlying: Common Stock · 128 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning April 9, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:51 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionCommon Stock | 128 | $65.36 | $8,366.08 |
DisclosureSEC source: 0001209191-20-063508 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This includes an aggregate of 23,784 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:19 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
Tax withholdingCommon Stock | 720 | $82.05 | $59,076.00 |
DisclosureSEC source: 0001209191-20-063210 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,522 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 21,565 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:58 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059156 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,013 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 21,700 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 22:03 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059167 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,851 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 96,700 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:55 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059152 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,700 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 96,700 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:38 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059127 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,818 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 23,784 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:46 UTC |
Stamoulis ChristianaEVP & Chief Financial Officer
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059139 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,299 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 19,875 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:35 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059122 · doc4.xml · nonDerivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,158 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 21,700 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:30 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantCommon Stock | 7,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059104 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,306 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020 this includes an aggregate of 120,195 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:16 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059070 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,242 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 23,284 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:20 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059084 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,216 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 26,521 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:56 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 127 | $0.00 Strike: $65.36 | $0.00 |
DisclosureSEC source: 0001209191-20-058483 · doc4.xml · derivative · entry 2 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,186 Underlying: Common Stock · 127 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning April 9, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:56 UTC |
Pasquale Maria EEVP & General Counsel
|
Exercise / conversionCommon Stock | 127 | $65.36 | $8,300.72 |
DisclosureSEC source: 0001209191-20-058483 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This includes an aggregate of 22,552 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.